Shanghai, China

Shen Jingshan


 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2012-2013

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Shen Jingshan: Innovator in Isoquinolinium Compounds

Introduction

Shen Jingshan is a notable inventor based in Shanghai, China. He has made significant contributions to the field of medicinal chemistry, particularly in the development of isoquinolinium compounds. With a total of 2 patents, his work has implications for the preparation of important pharmaceutical compounds.

Latest Patents

Shen's latest patents include innovative methods and compounds that are crucial for the production of cisatracurium. The first patent focuses on isoquinolinium compounds that are useful in the preparation of cisatracurium and its associated intermediates. This invention provides novel isoquinolinium compounds that can be obtained in solid form, allowing for purification through simple techniques. This process enables the production of pure cisatracurium besylate without the need for HPLC purification. The second patent outlines processes for producing cisatracurium compounds and their associated intermediates, further enhancing the efficiency of pharmaceutical manufacturing.

Career Highlights

Shen Jingshan is currently associated with Chemagis Ltd., where he continues to innovate in the field of drug development. His expertise in isoquinolinium compounds has positioned him as a key player in the pharmaceutical industry.

Collaborations

Shen has collaborated with notable colleagues, including Vladimir Naddaka and Oded Arad. These partnerships have fostered a collaborative environment that enhances the research and development of new pharmaceutical solutions.

Conclusion

Shen Jingshan's contributions to the field of medicinal chemistry, particularly through his patents on isoquinolinium compounds, demonstrate his commitment to advancing pharmaceutical science. His work not only showcases his innovative spirit but also has the potential to impact the development of critical medications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…